Fate Therapeutics (FATE) said late Friday that preclinical data for its CAR T-cell candidate FT836 demonstrated the product's potential for durable anti-tumor activity without intervention.
The data "support the pan-cancer activity of MICA/B targeting, and indicate that our next-generation, iPSC-derived CAR T-cell platform has the potential to drive potent and durable anti-tumor activity without the need for administration of conditioning chemotherapy to deplete host immune cells," Bob Valamehr, head of research and development at Fate, said in a statement.
Fate presented the data at the annual meeting of the Society of Immunotherapy of Cancer in Houston.
FT836 combines multiple next-generation synthetic controls of CAR T-cell function including a novel "Sword & Shield" technology "to address critical challenges that have limited CAR T cell safety and efficacy in treating solid tumors," the company said.
Price: 2.47, Change: +0.05, Percent Change: +2.07
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。